{"entity":{"id":"nct06732531","kind":"trial","name":"Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer","aka":[],"tldr":"A phase 1/2 trial of BH011 in bladder & urothelial cancer, run by Zhuhai Beihai Biotech Co., Ltd, now recruiting.","summary":"Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer is a phase 1/2 interventional study registered as NCT06732531 by Zhuhai Beihai Biotech Co., Ltd, with 48 participants planned, started 2022-08-03 and due to reach its primary completion in 2025-12. Interventions recorded: BH011.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06732531","url":"https://clinicaltrials.gov/study/NCT06732531"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06732531","phase":"1/2","setting":"A Phase I/II, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of BH011 in Subjects With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmette-Guérin","sponsor":"Zhuhai Beihai Biotech Co., Ltd","enrolled":48,"outcomes":[]},"route":"/trials/nct06732531/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}]}}